. Laboratory abnormalities in an 83-year-old female with West Nile encephalitis and profound and prolonged lymphocytopenia. 
Profound and Prolonged Lymphocytopenia with West Nile Encephalitis
An outbreak of West Nile encephalitis (WNE) occurred in the New York area during the summer of 1999 [1] . At our institution, 4 serologically proven cases of WNE were detected by use of enzyme immunoassay and plaque reduction neutralization test (titer range, 1:80-1:2560). All patients had encephalitis, and 1 patient had seizures. All had fever (temperature, р39ЊC [102ЊF]), and 1 had relative bradycardia. Three of the 4 patients were women (age range, 56-83 years). Of the 2 patients who had muscle weakness, 1 had flaccid paralysis. Only 1 patient had cervical adenopathy, and none had a skin rash or conjunctivitis. Nausea and vomiting were present in 2 patients, and nonexudative pharyngitis was present in 1 patient. Our patients with WNE differed from patients with WNE in Europe, Africa, and Asia, in that all of our patients had encephalitis and none had rash or submental adenopathy [2] [3] [4] [5] [6] . Laboratory abnormalities included leukocytosis in 2 patients and mild, transient thrombocytopenia in 3 of 4 patients. Mildly elevated serum transaminase levels occurred early in 3 patients. These laboratory abnormalities are consistent with previously reported cases of WNE occurring outside of North America. We were struck by the presence of relative lymphocytopenia in all 4 of our patients. None were receiving immunosuppressive therapy or had underlying conditions associated with lymphocytopenia (table 1) .
Relative lymphocytopenia may accompany a variety of disorders and may occur in patients with meningitis/non-WNE viral encephalitis [7] [8] [9] [10] . However, in all of our patients, lymphocytopenia was profound and prolonged; this feature has not been found among non-North American cases. In our laboratory, relative lymphocytopenia is defined as the presence of р20% lymphocytes on the peripheral smear. The lowest relative lymphocyte differential counts in our patients ranged from 5% to 9%, and lymphocytopenia persisted for the duration of the infection (e.g., 5-52 days). The absolute lymphocyte counts of our patients ranged from 385 to 1870 cells/mm 3 (normal range, 800-5600 cells/mm 3 ). The lymphocytopenia associated with most acute infectious diseases is usually mild and reverses rapidly, but, among our patients, lymphocytopenia was profound and prolonged; in 1 patient, it persisted for 52 days (figure 1).
In the outbreak that occurred in greater New York City in the late summer months of 1999, WNE was not initially recognized because it occurred in the midst of the usual seasonal increase in the number of cases of enteroviral meningitis together with cases of herpes simplex virus 1 (HSV-1) encephalitis, which occurs sporadically throughout the year. HSV-1 encephalitis may be differentiated from WNE by the presence of focal abnormalities on the electroencephalogram and/or on CT/MRI scans. Most cases of enteroviral meningitis are not accompanied by encephalitis, but enteroviral infections of the CNS are frequently accompanied by nonexudative pharyngitis, loose stools, or a maculopapular rash. Neither of these viral infections that infect the CNS is accompanied by lymphocytopenia. Although our series is limited, we believe that profound and prolonged lymphocytopenia in patients with encephalitis is an important diagnostic clue of WNE. In patients with encephalitis, aseptic meningitis, and profound lymphocytopenia, clinicians should rule out enteroviral meningoencephalitis and HSV-1 encephalitis and should order specific WNE serological testing. The first trial was a randomized study comparing the efficacy and safety of ABLC and fluconazole as prophylaxis for fungal infections in bone marrow transplant recipients. Unfortunately, this trial was prematurely discontinued because of unacceptable nephrotoxicity when ABLC prophylaxis was used for patients receiving cyclosporine prophylaxis. Patients who received ABLC prophylaxis also had frequent chills and fever; these toxicities were not observed in patients who received fluconazole prophylaxis." Dr. Winston was an investigator for such a proposed study in 1994. Actual enrollment of patients in the comparative phase of the study was never initiated; therefore, we are puzzled by Dr. Winston's comments regarding nephrotoxicity data from a comparative study that never took place.
The second study cited by Winston and Schiller, a study comparing amphotericin B with ABLC (Abelcet; Liposome, Princeton, NJ) for the empiric treatment of patients with febrile neutropenia, was initiated in the United States. Enrollment in this study was discontinued in 1995 because of study-design issues and related investigator protocol violations. The study was also discontinued as a result of the Liposome Company's internal management decision to focus the clinical development of Abelcet on the treatment of confirmed fungal infection in patients who cannot tolerate or who do not respond to conventional antifungal therapy.
Given the high percentage of protocol violations in the study, a formal analysis of these data has not been conducted, and findings from such a database would be potentially misleading. Despite the early termination of this study, Dr. Winston was provided with the individual data listings for patients enrolled at this site. The data to which Drs. Winston and Schiller refer reflect a very limited patient enrollment at their center (12 patients treated with amphotericin B and 13 treated with amphotericin B lipid complex). In such a limited number of patients, a comparison of the safety and efficacy of treatment for febrile neutropenia would not be expected to demonstrate a statistically significant difference in outcome. Indeed, the Mycosis Study Group's recently completed study of treatment with AmBisome versus conventional amphotericin required the enrollment of 1700 patients to have statistical power to detect potential differences between the 2 products when they are used for the empiric treatment of fungal infections in patients with febrile neutropenia [2] .
During the past 4 years, 180,000 patients who have had proven infection and who have either failed or developed in-
